Recent advances in immuno-oncology have the potential to transform the practice of medical oncology. Antibodies directed against negative regulators of T-cell function (checkpoint inhibitors), engineered cell therapies and innate immune stimulators, such as oncolytic viruses, are effective in a wide ...
Recent advances in immuno-oncology have the potential to transform the practice of medical oncology. Antibodies directed against negative regulators of T-cell function (checkpoint inhibitors), engineered cell therapies and innate immune stimulators, such as oncolytic viruses, are effective in a wide ...
they are more labor-intensive and have lower throughput than pooled arrays; thereby, studies extensively apply pooled screens for discovery. CRISPR has unraveled several molecules in the immune-oncology field. Therefore, we list the recent findings...
Recent clinical trials, especially of ICIs targeting programmed death protein 1 (PD-1) and PD ligand-1(PD-L1), have shown their noteworthy efficacy in GI tract cancers and have contributed to a paradigm shift in treatment principles. Notwithstanding the anti-PD-1/PD-L1 treatment patterns of s...
Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. Pharm Med 34, 83–91 (2020). https://doi.org/10.1007/s40290-020-00326-z Download citation Published10 March 2020 Issue DateApril 2020 DOIhttps://doi.org/10.1007/s40290-020-00326-z...
Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care Spotlight - In-person and virtual events just for HCPs CME Opportunities Choose Specialty
Context Prostate cancer (PCa) is the second largest male tumor in the world and one of the most common malignant tumors in the urinary system. In recent years, the incidence rate of PCa in China has been increasing year by year. Meanwhile, refractory hormone resistance and adverse drug reacti...
(mRECIST). Eastern Cooperative Oncology Group performance status of 0 or 1. They do not have an active, known, or suspected autoimmune disease. And do not show Grade ≥ 3 autoimmune manifestations of previous immune checkpoint inhibitor treatments (e.g., anti-PD-1, anti-PD-L1, or ...
“cytotoxicity”). This precision medicine approach leads to higher response rates and increased chances of remission, which is nothing short of revolution in the oncology field. It is especially remarkable considering that Dr. Rosenberg discovered TIL’s cytotoxicity ~ 40 years ago without many ...
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy ArticleOpen access03 April 2020 Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons Introduction The cancer burden is a crucial global public health problem, which exerts tremendous physical...